# Immunotherapy-Based Combination Therapy for the Successful Treatment of Coexisting Primary and Axillary Accessory Breast Cancers: A Case Report

**Authors:** Yuko Tanaka, Yoshio Suzuki

PMC · DOI: 10.7759/cureus.83340 · Cureus · 2025-05-02

## TL;DR

A 70-year-old woman was successfully treated for two coexisting breast cancers using immunotherapy targeting PD-L1.

## Contribution

This is the first reported case of synchronous ipsilateral breast and axillary accessory breast cancer successfully treated with immunotherapy.

## Key findings

- The patient had luminal A subtype breast cancer and triple-negative axillary accessory breast cancer.
- The axillary tumor showed high PD-L1 expression and responded well to immunotherapy.
- The case emphasizes the importance of recognizing accessory breast cancer as a distinct clinical entity.

## Abstract

Accessory breast cancer is a relatively rare condition, and to our knowledge, no previous reports have described synchronous ipsilateral cancers of the breast and the axillary accessory breast. We report a unique case involving a 70-year-old female patient with luminal A subtype breast cancer and triple-negative accessory breast cancer. The axillary tumor, which had become ulcerative and exudative, was diagnosed as an accessory breast cancer with high Programmed Cell Death Ligand 1 (PD-L1) expression. Treatment with immune checkpoint inhibitors targeting PD-L1 was effective. This case highlights the clinical importance of considering accessory breast cancer as a distinct entity and demonstrates the potential utility of immunotherapy in such cases.

## Linked entities

- **Proteins:** CD274 (CD274 molecule)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}
- **Diseases:** Accessory breast cancer (MESH:D001943), ulcerative (MESH:D014456), axillary tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12127700/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12127700/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12127700/full.md

---
Source: https://tomesphere.com/paper/PMC12127700